INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Recommendation of “Buy” from Analysts

INmune Bio, Inc. (NASDAQ:INMB) has been assigned an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $22.80.

Several research firms have issued reports on INMB. Maxim Group raised their target price on INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Rodman & Renshaw began coverage on INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 target price for the company. Scotiabank raised their target price on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, February 11th. Finally, RODMAN&RENSHAW upgraded INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th.

INmune Bio Stock Down 1.1 %

INMB stock opened at $7.95 on Monday. The business has a fifty day moving average of $8.00 and a two-hundred day moving average of $6.27. The stock has a market cap of $211.40 million, a price-to-earnings ratio of -3.65 and a beta of 1.93. INmune Bio has a 52-week low of $4.32 and a 52-week high of $12.72.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Praetorian PR LLC boosted its position in shares of INmune Bio by 61.0% during the third quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock worth $4,209,000 after buying an additional 295,800 shares during the period. Raymond James Financial Inc. purchased a new position in INmune Bio in the fourth quarter valued at $2,221,000. Geode Capital Management LLC boosted its holdings in INmune Bio by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 363,602 shares of the company’s stock valued at $1,698,000 after purchasing an additional 19,136 shares during the period. Millennium Management LLC boosted its holdings in INmune Bio by 43.9% in the fourth quarter. Millennium Management LLC now owns 291,327 shares of the company’s stock valued at $1,360,000 after purchasing an additional 88,823 shares during the period. Finally, State Street Corp boosted its holdings in INmune Bio by 35.1% in the third quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after purchasing an additional 58,838 shares during the period. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.